Raises Full Year Revenue and Maintains Adjusted EBITDA Guidance Excluding Aqua Divestiture Second Quarter 2024 Financial Results Revenue of $1,184 million Reported Net Loss of $50 million , Adjusted Net Income of $147 million Adjusted EBITDA of $275 million , or 23.2% of Revenue Reported EPS of $(0.10) , Adjusted EPS of $0.
30 Net leverage ratio of 5.6x Adjusted EBITDA Year over year growth rates are meaningfully impacted by a shift in customer purchasing related to the ERP Blackout in 2023, with an estimated $90 to $110 million of revenue shift from the second quarter of 2023 into the first quarter of 2023 Updating full year 2024 financial guidance to reflect aqua divestiture and expected contribution from Bovaer and Zenrelia: Revenue of $4,410 to $4,460 million , with organic constant currency growth raised to 3% to 4% Reported Net Income of $314 to $352 million ; Reported EPS of $0.63 to $0.
71 Adjusted EBITDA of $900 to $940 million ; Adjusted EPS of $0.88 to $0.96 Completed sale of aqua business in July, resulting in $1.
2 billion of debt paydown in the third quarter of 2024 Zenrelia, a JAK inhibitor targeting control of pruritus and atopic dermatitis in dogs, has been submitted to the FDA, initiating the final 60-day administrative review period with approval expected in late September GREENFIELD, Ind. , Aug. 8, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN ) today reported financial results for the second quarter of 2024, provided guidance for the thi.